TY - JOUR
T1 - Necrotic reshaping of the glioma microenvironment drives disease progression
AU - Markwell, Steven M.
AU - Ross, James L.
AU - Olson, Cheryl L.
AU - Brat, Daniel J.
N1 - Funding Information:
This work was supported by the National Institutes of Health (DJB; R01 CA214928, R01 CA247905, P50 CA221747, U01 CA217613 and U01 CA199288) and the Cancer Research Institute Irvington Fellowship (JLR). Illustrations were created by Andrea Charest, MS using Adobe Illustrator in collaboration with the authors.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/3
Y1 - 2022/3
N2 - Glioblastoma is the most common primary brain tumor and has a dismal prognosis. The development of central necrosis represents a tipping point in the evolution of these tumors that foreshadows aggressive expansion, swiftly leading to mortality. The onset of necrosis, severe hypoxia and associated radial glioma expansion correlates with dramatic tumor microenvironment (TME) alterations that accelerate tumor growth. In the past, most have concluded that hypoxia and necrosis must arise due to “cancer outgrowing its blood supply” when rapid tumor growth outpaces metabolic supply, leading to diffusion-limited hypoxia. However, growing evidence suggests that microscopic intravascular thrombosis driven by the neoplastic overexpression of pro-coagulants attenuates glioma blood supply (perfusion-limited hypoxia), leading to TME restructuring that includes breakdown of the blood–brain barrier, immunosuppressive immune cell accumulation, microvascular hyperproliferation, glioma stem cell enrichment and tumor cell migration outward. Cumulatively, these adaptations result in rapid tumor expansion, resistance to therapeutic interventions and clinical progression. To inform future translational investigations, the complex interplay among environmental cues and myriad cell types that contribute to this aggressive phenotype requires better understanding. This review focuses on contributions from intratumoral thrombosis, the effects of hypoxia and necrosis, the adaptive and innate immune responses, and the current state of targeted therapeutic interventions.
AB - Glioblastoma is the most common primary brain tumor and has a dismal prognosis. The development of central necrosis represents a tipping point in the evolution of these tumors that foreshadows aggressive expansion, swiftly leading to mortality. The onset of necrosis, severe hypoxia and associated radial glioma expansion correlates with dramatic tumor microenvironment (TME) alterations that accelerate tumor growth. In the past, most have concluded that hypoxia and necrosis must arise due to “cancer outgrowing its blood supply” when rapid tumor growth outpaces metabolic supply, leading to diffusion-limited hypoxia. However, growing evidence suggests that microscopic intravascular thrombosis driven by the neoplastic overexpression of pro-coagulants attenuates glioma blood supply (perfusion-limited hypoxia), leading to TME restructuring that includes breakdown of the blood–brain barrier, immunosuppressive immune cell accumulation, microvascular hyperproliferation, glioma stem cell enrichment and tumor cell migration outward. Cumulatively, these adaptations result in rapid tumor expansion, resistance to therapeutic interventions and clinical progression. To inform future translational investigations, the complex interplay among environmental cues and myriad cell types that contribute to this aggressive phenotype requires better understanding. This review focuses on contributions from intratumoral thrombosis, the effects of hypoxia and necrosis, the adaptive and innate immune responses, and the current state of targeted therapeutic interventions.
KW - Glioblastoma
KW - Necrosis
KW - Tumor-associated macrophages
UR - http://www.scopus.com/inward/record.url?scp=85123110782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123110782&partnerID=8YFLogxK
U2 - 10.1007/s00401-021-02401-4
DO - 10.1007/s00401-021-02401-4
M3 - Review article
C2 - 35039931
AN - SCOPUS:85123110782
SN - 0001-6322
VL - 143
SP - 291
EP - 310
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 3
ER -